


Bill C-45: The Cannabis Act

<https://policybase.cma.ca/link/policy13861>

POLICY TYPE	Parliamentary submission
DATE	2018-04-18
TOPICS	Pharmaceuticals, prescribing, cannabis, drugs

Documents




CMA's Recommendations for Bill S-5 An Act to amend the Tobacco Act and the Non-smokers' Health Act and to make consequential amendments to other Acts

<https://policybase.cma.ca/link/policy13918>

POLICY TYPE	Parliamentary submission
DATE	2018-02-15
TOPICS	Pharmaceuticals, prescribing, cannabis, drugs Health care and patient safety

Documents



Consultation on proposed front-of-package labelling

<https://policybase.cma.ca/link/policy13882>

POLICY TYPE Response to consultation
DATE 2018-04-23
TOPICS Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents




Health Canada consultation on Canadian drugs and substances strategy

<https://policybase.cma.ca/link/policy14017>

POLICY TYPE	Response to consultation
DATE	2018-12-04
TOPICS	Pharmaceuticals, prescribing, cannabis, drugs Population health, health equity, public health

Documents




Health Canada consultation on regulatory amendments regarding tramadol

<https://policybase.cma.ca/link/policy13927>

POLICY TYPE Response to consultation
DATE 2018-08-14
TOPICS Pharmaceuticals, prescribing, cannabis, drugs

Documents




Health Canada consultation on restriction of marketing and advertising of opioids

<https://policybase.cma.ca/link/policy13921>

POLICY TYPE	Response to consultation
DATE	2018-07-18
TOPICS	Pharmaceuticals, prescribing, cannabis, drugs

Documents




Health Canada consultation on tobacco products regulations (plain and standardized appearance)

<https://policybase.cma.ca/link/policy13930>

POLICY TYPE	Response to consultation
DATE	2018-09-06
TOPICS	Health care and patient safety Pharmaceuticals, prescribing, cannabis, drugs

Documents




Implementation of National Pharmacare

<https://policybase.cma.ca/link/policy13933>

POLICY TYPE	Response to consultation
DATE	2018-10-02
TOPICS	Health care and patient safety Pharmaceuticals, prescribing, cannabis, drugs

Documents




Proposed approach to the regulation of cannabis

<https://policybase.cma.ca/link/policy13838>

POLICY TYPE	Response to consultation
DATE	2018-01-19
TOPICS	Pharmaceuticals, prescribing, cannabis, drugs

Documents



Support life-saving supervised consumption and overdose prevention sites: open letter to Premier Doug Ford and Health Minister Christine Elliott

<https://policybase.cma.ca/link/policy13931>

POLICY TYPE	Policy endorsement
DATE	2018-08-30
TOPICS	Pharmaceuticals, prescribing, cannabis, drugs

Documents

The image shows a thumbnail of a document titled "Support life-saving supervised consumption and overdose prevention sites: open letter to Premier Doug Ford and Health Minister Christine Elliott". The document is dated August 30, 2018, and is addressed to the Premier and Health Minister. It discusses the need for supervised consumption sites (SCS) and overdose prevention sites (OPS) in Ontario, citing evidence that these services save lives and prevent health issues. It also mentions that multiple reviews of the evidence have already been done and have established that SCS and OPS provide a needed health service, reduce overdose deaths, and the sharing of drug-injection equipment (and the associated risk of transmission of blood-borne infections). The document also notes that as you know Canada is experiencing a large-scale opioid overdose crisis, in Ontario alone, overdose deaths related to opioids increased by 41 per cent in 2017, with more than three people dying every day during that year. The opioid overdose epidemic has been called "the worst drug safety crisis in Canadian history." HIV, hepatitis C and other infections, as well as overdose deaths, are preventable if the right measures are taken. These include increasing voluntary access to treatment for problematic drug use (where Ontario must do better), and also simultaneously scaling up evidence-based harm reduction services such as SCS and OPS. The document concludes by urging you to heed the recommendations of experts in public health, front-line clinicians, harm reduction staff, and people with lived experience of drug use. Rather than impeding access to life-saving health services, we urge you to work with community organizations and other health services providers to ensure greater, equitable access to SCS and OPS for the people of Ontario.